

WEST**End of Result Set**

Generate Collection

Print

L1: Entry 1 of 1

File: USPT

Feb 26, 2002

US-PAT-NO: 6350615

DOCUMENT-IDENTIFIER: US 6350615 B1

TITLE: Gene product over expressed in cancer cells

DATE-ISSUED: February 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kaufman; Russel E.	Durham	NC		
Slentz-Kesler; Kimberly	Durham	NC		

US-CL-CURRENT: 436/86; 530/350

CLAIMS:

What is claimed is:

1. A method of screening a compound for its ability to modulate K12 protein growth promoting activity comprising incubating K12 protein, or portion thereof having growth promoting activity, with cells susceptible to the growth promoting activity of K12 protein, in the presence and absence of said compound, and assaying for an alteration in the growth rate of said cells in the presence of said compound,

a reduction in the growth rate of said cells being indicative of a compound that modulates said growth promoting activity,

wherein said K12 protein is selected from the group consisting of growth promoting activity and the amino acid sequence set forth in SEQ ID NO:1 and a protein having an amino acid sequence encoded by a nucleic acid sequence that hybridizes to the nucleic acid sequence set forth in SEQ ID NO:2 at 55.degree. C. in 3.times. saline/sodium citrate comprising 0.1% sodium dodecylsulfate and that remains hybridized when subjected to washing at 55.degree. C. with 1.times. SSC comprising 0.1% SDS.

WEST**End of Result Set**

Generate Collection

Print

L3: Entry 1 of 1

File: USPT

Jun 15, 1999

US-PAT-NO: 5912142

DOCUMENT-IDENTIFIER: US 5912142 A

TITLE: Gene product over expressed in cancer cells

DATE-ISSUED: June 15, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kaufman; Russel E.	Durham	NC		
Slentz-Kesler; Kimberly	Durham	NC		

US-CL-CURRENT: 435/69.1, 435/252.3, 435/254.2, 435/320.1, 435/325, 530/350, 536/23.1, 536/23.5

CLAIMS:

What is claimed is:

1. An isolated nucleic acid having a sequence: i) that encodes a human K12 protein having the amino acid sequence set forth in SEQ ID NO:1, or ii) that hybridizes to the nucleic acid sequence set forth in SEQ ID NO:2 at 55.degree. C. in 3.times. saline/sodium citrate (SSC) comprising 0.1% sodium dodecylsulfate (SDS) and that remains hybridized when subjected to washing at 55.degree. C. with 1.times. SSC comprising 0.1% SDS.
2. The nucleic acid according to claim 1 wherein said nucleic acid has a sequence that encodes said human K12 protein having the amino acid sequence set forth in SEQ ID NO:1.
3. An isolated nucleic acid having a sequence that encodes a human K12 protein having the amino acid sequence set forth in SEQ ID NO:1, or portion of said amino acid sequence set forth in SEQ ID NO:1 of at least 10 consecutive amino acids.
4. The isolated nucleic acid according to claim 3 wherein the nucleic acid encodes the human K12 protein having the amino acid sequence set forth in SEQ ID NO:1, or portion of said amino acid sequence set forth in SEQ ID NO:1 of at least 50 consecutive amino acids.
5. The isolated nucleic acid according to claim 4 wherein the nucleic acid has the sequence shown in SEQ ID NO:2, or portion of the sequence shown in SEQ ID NO:2 of at least 30 consecutive bases.
6. The isolated nucleic acid according to claim 5 wherein the nucleic acid has the sequence shown in SEQ ID NO:2.
7. A recombinant molecule comprising a nucleic acid having a sequence: i) that encodes a human K12 protein having the amino acid sequence set forth in SEQ ID NO:1, or ii) that hybridizes to the nucleic acid sequence set forth in SEQ ID

NO:2 at 55.degree. C. in 3.times. saline/sodium citrate (SSC) comprising 0.1% sodium dodecylsulfate (SDS) and that remains hybridized when subjected to washing at 55.degree. C. with 1.times. SSC comprising 0.1% SDS, and a vector.

8. The recombinant molecule according to claim 7 further comprising a promoter operably linked to said nucleic acid sequence.

9. A host cell comprising said recombinant molecule according to claim 7.

10. A method of producing a human K12 protein comprising culturing said host cell according to claim 9, wherein said nucleic acid has a sequence that encodes said human K12 protein, under conditions such that said nucleic acid sequence is expressed and said human K12 protein is thereby produced.

11. A recombinant molecule comprising a nucleic acid having a sequence that encodes a human K12 protein having the amino acid sequence set forth in SEQ ID NO:1, or portion of said amino acid sequence set forth in SEQ ID NO:1 of at least 10 consecutive amino acids, and a vector.

12. The recombinant molecule according to claim 11 further comprising a promoter operably linked to said nucleic acid sequence.

13. A host cell comprising said recombinant molecule according to claim 11.

14. A method of producing a human K12 protein, or portion thereof, comprising culturing said host cell according to claim 13 under conditions such that said nucleic acid sequence is expressed and said human K12 protein, or portion thereof, is thereby produced.

WEST**End of Result Set**

Generate Collection

Print

L2: Entry 1 of 1

File: USPT

Jun 6, 2000

US-PAT-NO: 6072034

DOCUMENT-IDENTIFIER: US 6072034 A

TITLE: Gene product over expressed in cancer cells

DATE-ISSUED: June 6, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kaufman; Russel E.	Durham	NC		
Slentz-Kesler; Kimberly	Durham	NC		

US-CL-CURRENT: 530/350; 435/252.33, 435/320.1, 435/69.1, 530/300, 536/23.5

CLAIMS:

What is claimed is:

1. An isolated protein: i) that has the amino acid sequence set forth in SEQ ID NO:1, or ii) that has an amino acid sequence encoded by a nucleic acid sequence that hybridizes to the nucleic acid sequence set forth in SEQ ID NO:2 at 55.degree. C. in 3.times.saline/sodium citrate (SSC) comprising 0.1% sodium dodecylsulfate (SDS) and that remains hybridized when subjected to washing at 55.degree. C. with 1.times.SSC comprising 0.1% SDS.
2. The protein according to claim 1 wherein said protein has the amino acid sequence set forth in SEQ ID NO:1.
3. An isolated protein having the amino acid sequence set forth in SEQ ID NO:1, or portion of said amino acid sequence set forth in SEQ ID NO 1 of at least 10 consecutive amino acids.
4. The protein according to claim 3 wherein said protein has the amino acid sequence set forth in SEQ ID NO:1, or portion of said amino acid sequence set forth in SEQ ID NO:1 of at least 50 consecutive amino acids.
5. The protein according to claim 3 wherein said protein has the amino acid sequence set forth in SEQ ID NO:1, or portion of said amino acid sequence set forth in SEQ ID NO:1 of at least 100 consecutive amino acids.
6. The protein according to claim 3 wherein said protein has the amino acid sequence set forth in SEQ ID NO:1, or portion of said amino acid sequence set forth in SEQ ID NO:1 of at least 240 consecutive amino acids.
7. A fusion protein comprising a protein: i) that has the amino acid sequence set forth in SEQ ID NO:1, or ii) that has an amino acid sequence encoded by a nucleic acid sequence that hybridizes to the nucleic acid sequence set forth in SEQ ID NO:2 at 55.degree. C. in 3.times.saline/sodium citrate (SSC) comprising 0.1% sodium dodecylsulfate (SDS) and that remains hybridized when subjected to washing at 55.degree. C. with 1.times.SSC comprising 0.1% SDS.

8. The fusion protein according to claim 7 wherein said protein has the amino acid sequence set forth in SEQ ID NO:1.
9. A composition comprising a protein: i) that has the amino acid sequence set forth in SEQ ID NO:1, or ii) that has an amino acid sequence encoded by a nucleic acid sequence that hybridizes to the nucleic acid sequence set forth in SEQ ID NO:2 at 55.degree. C. in 3.times.saline/sodium citrate (SSC) comprising 0.1% sodium dodecylsulfate (SDS) and that remains hybridized when subjected to washing at 55.degree. C. with 1.times.SSC comprising 0.1% SDS, and a pharmaceutically acceptable carrier.
10. The composition according to claim 9 wherein said protein has the amino acid sequence set forth in SEQ ID NO:1.
11. The composition according to claim 9 wherein said composition is a pharmaceutical composition and said carrier is a pharmaceutically acceptable carrier.
12. The composition according to claim 10 wherein said composition is a pharmaceutical composition and said carrier is a pharmaceutically acceptable carrier.
13. A fusion protein comprising a protein having the amino acid sequence set forth in SEQ ID NO:1, or portion of said amino acid sequence set forth in SEQ ID NO:1 of at least 10 consecutive amino acids.
14. The fusion protein according to claim 13 wherein said protein has the amino acid sequence set forth in SEQ ID NO:1, or portion of said amino acid sequence set forth in SEQ ID NO:1 of at least 50 consecutive amino acids.
15. The fusion protein according to claim 13 wherein said protein has the amino acid sequence set forth in SEQ ID NO:1, or portion of said amino acid sequence set forth in SEQ ID NO:1 of at least 100 consecutive amino acids.
16. An fusion protein according to claim 13 wherein said protein has the amino acid sequence set forth in SEQ ID NO:1, or portion of said amino acid sequence set forth in SEQ ID NO:1 of at least 240 consecutive amino acids.